<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Time to platelet count response for immune thrombocytopenia treatments</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Time to platelet count response for immune thrombocytopenia treatments</h1>
<div class="graphic"><div class="figure"><div class="ttl">Time to platelet count response for immune thrombocytopenia treatments</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1"> </td> <td class="subtitle1">Treatment</td> <td class="subtitle1">Initial response* (days)</td> <td class="subtitle1">Peak <span class="nowrap_whitespace">response<sup>¶</sup></span> (days)</td> </tr> <tr> <td class="align_middle divider_bottom" rowspan="4"><strong>First-line therapies</strong></td> <td>Dexamethasone</td> <td class="centered">2 to 14</td> <td class="centered">4 to 28</td> </tr> <tr> <td>Prednisone</td> <td class="centered">4 to 14</td> <td class="centered">7 to 28</td> </tr> <tr> <td>IVIG</td> <td class="centered">1 to 3</td> <td class="centered">2 to 7</td> </tr> <tr class="divider_bottom"> <td>Anti-D</td> <td class="centered">1 to 3</td> <td class="centered">3 to 7</td> </tr> <tr> <td class="align_middle divider_bottom" rowspan="5"><strong>Second-line therapies</strong></td> <td>Splenectomy</td> <td class="centered">1 to 56</td> <td class="centered">7 to 56</td> </tr> <tr> <td>Rituximab</td> <td class="centered">7 to 56</td> <td class="centered">14 to 180</td> </tr> <tr> <td>Avatrombopag</td> <td class="centered">3 to 5<sup>Δ</sup></td> <td class="centered">13 to 16</td> </tr> <tr> <td>Eltrombopag</td> <td class="centered">7 to 14<sup>Δ</sup></td> <td class="centered">14 to 90</td> </tr> <tr class="divider_bottom"> <td>Romiplostim</td> <td class="centered">7 to 14<sup>Δ</sup></td> <td class="centered">14 to 60</td> </tr> <tr> <td class="align_middle" rowspan="6"><strong>Other therapies</strong></td> <td>Azathioprine</td> <td class="centered">30 to 90</td> <td class="centered">30 to 180</td> </tr> <tr> <td>Danazol</td> <td class="centered">14 to 90</td> <td class="centered">28 to 180</td> </tr> <tr> <td>Fostamatinib</td> <td class="centered">15</td> <td class="centered"> </td> </tr> <tr> <td>MMF</td> <td class="centered"> </td> <td class="centered"> </td> </tr> <tr> <td>Vinblastine</td> <td class="centered">7 to 14</td> <td class="centered">7 to 42</td> </tr> <tr> <td>Vincristine</td> <td class="centered">7 to 14</td> <td class="centered">7 to 42</td> </tr> </tbody></table></div><div class="graphic_lgnd">The expected time to initial response and peak response with various ITP treatments are listed. Treatments are listed in order of approximate rapidity of the expected initial response. Peak response reflects the time after which response becomes less likely at typically used doses. These data do not address the quality of the response (ie, absolute platelet count reached or percent increase from baseline) or the likelihood of a response for any given treatment. Refer to UpToDate for details of our approach to the initial and subsequent treatment of ITP and the overall efficacy of these treatments.</div><div class="graphic_footnotes"><p>ITP: immune thrombocytopenia; IVIG: intravenous immune globulin; TPO-RA: thrombopoietin receptor agonist.</p>
<p>* Initial response is the first time that a response could be reasonably expected.</p>
<p>¶ Peak response is the time after which a response becomes less likely at typically used doses.</p>
Δ TPO-RA dose should be titrated upward until an adequate platelet count is achieved or maximum dose is reached.</div><div class="graphic_reference"><p>This table was adapted from research originally published in Blood. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386. Copyright © 2009 American Society of Hematology.</p>
Updated with information from:
<ol>
<li>Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190.</li>
<li>Dlugosz-Danecka M, Zdziarska J, Jurczak W. Avatrombopag for the treatment of immune thrombocytopenia. Expert Rev Clin Immunol 2019; 15:327.</li>
<li>McBride A, Nayak P, Kreychman Y, et al. Fostamatinib disodium hexahydrate: a novel treatment for adult immune thrombocytopenia. Am J Manag Care 2019; 25:S347.</li>
</ol></div><div id="graphicVersion">Graphic 87698 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
